Document is current

Any future updates will be listed below

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial

Crossref DOI link: https://doi.org/10.1186/2162-3619-3-26

Published Online: 2014-11-07

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark